|
|
|
13.06.25 - 10:15
|
Full-day Takeaway: HSI Closes at 23,892, Down 142 pts; HSTI Closes at 5,239, Down 91 pts; CHOW TAI FOOK Up over 5%; CHOW TAI FOOK, WUXI APPTEC, LUK FOOK HOLD, INNOCARE, WANGUO GOLD GP Hit New Highs; Market Turnover Rises (AAStocks)
|
|
|
At close, HSI dropped 142 pts or 0.6% to 23,892. HSTI dropped 91 pts or 1.7% to 5,239. HSCEI fell 74 pts or 0.9% to 8,655. Market turnover reached $294.29 billion.Active Heavyweights:BABA (09988.HK) closed at $112, down 2.3%MEITUAN (03690.HK) closed at $138.2, down 2%HKEX (00388.HK) closed at $413.6, up 0.5%CCB (00939.HK) closed......
|
|
|
21.05.25 - 06:15
|
Midday Takeaway: HSI Closes Midday at 23,807, Up 125 pts; HSTI Closes Midday at 5,338, Up 22 pts; ZHONGSHENG HLDG Up over 7%; GEELY AUTO, BYD COMPANY, HSBC HOLDINGS, SIMCERE PHARMA, INNOCARE Hit New Highs (AAStocks)
|
|
|
At midday close, HSI rose 125 pts or 0.5% to 23,807. HSTI rose 22 pts or 0.4% to 5,338. HSCEI gained 58 pts or 0.7% to 8,647.Active Heavyweights:HKEX (00388.HK) closed at $387.8, up 2.3%CCB (00939.HK) closed at $6.99, up 0.9%TENCENT (00700.HK) closed at $520, up 0.6%BABA (09988.HK) closed at $122.4, up 0.6%MEITUAN (03690.HK) clo......
|
|
|
16.05.25 - 10:06
|
Panel giant Innolux reorganizes leadership amid power struggle (Digitimes)
|
|
|
Innolux Corporation reappointed Jim Hung as chairman and CEO at its May 7 shareholders' meeting, while promoting Executive Vice President Jeffrey Yang to general manager. Former General Manager Zhu-Xiang Yang will now focus exclusively on leading subsidiary InnoCare Optoelectronics and serving as an Innolux director....
|
|
|
|
|
13.05.25 - 13:24
|
InnoCare′s Mesutoclax obtains breakthrough therapy designation in China (PBR)
|
|
|
This designation is intended for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). Mesutoclax becomes the inaugural BCL2 inhibitor to receive BTD recognition in
The post InnoCare's Mesutoclax obtains breakthrough therapy designation in China appeared first on Pharmaceutical Business review....
|
|
|
22.04.25 - 10:15
|
Full-day Takeaway: HSI Closes at 21,562, Up 167 pts; HSTI Closes at 4,899, Up 11 pts; MEITUAN Down over 4%; HK & CHINA GAS, INNOCARE, WANGUO GOLD GP, POP MART, CHINA EAST EDU Hit New Highs; Market Turnover Rises (AAStocks)
|
|
|
At close, HSI rose 167 pts or 0.8% to 21,562. HSTI rose 11 pts or 0.2% to 4,899. HSCEI gained 53 pts or 0.7% to 7,950. Market turnover reached $251.38 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $130.2, down 4.6%PING AN (02318.HK) closed at $44.7, up 2.1%BABA (09988.HK) closed at $110, up 1.2%CCB (00939.HK) closed a......
|
|
|
27.03.25 - 14:12
|
InnoCare Releases 2024 Results and Business Highlights (Business Wire)
|
|
|
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024.
Financial Highlights
Revenue of Orelabrutinib increased by 49.1% to RMB 1,000.4 million1 in 2024, mainly driven by rapid growth of marginal zone lymphoma (MZL) indication and strong commercial execution. Total revenue increased by 36.7% to RMB 1,009.4 million in 2024.
Gross Profit increased by 42.8% to RMB 871.0 million in 2024, with a gross profit margin of 86.3%, representing an increase of 3.7 percentage points, mainly due to the reduction in the unit cost of sales.
Research and Development Expenses increased by 8.4% to RMB 814.0 million in 2024, primarily due to increased investment in advanced technology platforms and heightened spending on global clinical trials.
The Loss decreased by 29.9% to RMB 452.9 million in 2024.
Cash and Related Accounts Balance2 stood at approximately RMB 7.8 bill...
|
|
|
17.03.25 - 09:06
|
InnoCare forecasts revenue share surge from IGZO panels in 2025 (Digitimes)
|
|
|
InnoCare Optoelectronics anticipates strong shipment growth for IGZO (Indium Gallium Zinc Oxide) panel products in 2025, driven by increasing adoption in dental and surgical equipment, including dynamic X-ray and C-arm systems. The company expects its IGZO product revenue share to exceed 30%, according to President Eric Lee....
|
|
|
11.11.24 - 09:57
|
Results: INNOCARE 1-3Q24 Loss Narrows to RMB275M (AAStocks)
|
|
|
INNOCARE (09969.HK) has announced its 1-3Q results ended September 2024. In accordance with China Accounting Standards for Business Enterprises, its turnover rose 29.8% YoY to RMB698 million, while its loss narrowed to RMB275 million, compared to a loss of RMB531 million in the same period last year. Its LPS stood at RMB0.16.~AA......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
